Showing 241 - 260 results of 449 for search '"clinical trial"', query time: 0.07s Refine Results
  1. 241

    Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

    Published 2025-02-01
    “…Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.…”
    Get full text
    Article
  2. 242

    A comprehensive review of remimazolam for sedation by Nazir Noor, Rhorer Legendre, Alexandra Cloutet, Ahish Chitneni, Giustino Varrassi, Alan D. Kaye

    Published 2021-06-01
    “…However, further large clinical trials will provide us with a better understanding of the advantages and disadvantages of remimazolam.…”
    Get full text
    Article
  3. 243

    Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia by A. A. Sheptulin, V. O. Kaybysheva

    Published 2015-10-01
    “…Mechanism of action includes effect on motility of the stomach and intestine, visceral sensitivity along with anti-inflammatory and cytoprotective effects. Controlled clinical trials have confirmed high efficacy of Iberogast® at treatment of FD (including pediatric practice) as well as good tolerability of the drug.Conclusion. …”
    Get full text
    Article
  4. 244

    From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases by Qing Zhao, Linxin Wei, Youxin Chen

    Published 2025-03-01
    “…This review summarizes the application strategies and delivery methods of CRISPR/Cas, discusses recent progress in CRISPR/Cas-based disease models and therapies, and provides an overview of the landscape of clinical trials. Current obstacles and future directions regarding the bench-to-bedside transition are also discussed.…”
    Get full text
    Article
  5. 245

    Improving drug repositioning with negative data labeling using large language models by Milan Picard, Mickael Leclercq, Antoine Bodein, Marie Pier Scott-Boyer, Olivier Perin, Arnaud Droit

    Published 2025-02-01
    “…Results We proposed a novel strategy using Large Language Models (GPT-4) to analyze all clinical trials on prostate cancer and systematically identify true negatives. …”
    Get full text
    Article
  6. 246

    Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives by Dong Luo, Yunmei Liu, Zhengmao Lu, Lei Huang

    Published 2025-02-01
    “…Innovative immunotherapy modalities, including adoptive immune cell therapy, tumor vaccines, and non-specific immunomodulators therapy, and oncolytic viruses have shown promise in early-stage clinical trials for GC. Clinical trials have supported that targeted therapy and immunotherapy can significantly improve the survival and quality of life of GC patients. …”
    Get full text
    Article
  7. 247

    Non-pharmacological interventions for the reduction and maintenance of blood pressure in people with prehypertension: a systematic review protocol by Paul Rutter, Andrew Clegg, Valerio Benedetto, Caroline Watkins, Nefyn Williams, Joseph Spencer, Lucy Hives, Emma P Bray, Cath Harris, Rachel F Georgiou, Nafisa Iqbal

    Published 2024-01-01
    “…The databases/trial registries that will be searched to identify relevant randomised controlled trials (RCTs) and economic evaluations include Medline, EMBASE, CINAHL, PsycINFO, CENTRAL, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, Cochrane Library, Scopus and the International HTA Database. …”
    Get full text
    Article
  8. 248

    Therapeutics in paediatric genetic diseases: current and future landscape by Ai Ling Koh, Saumya Shekhar Jamuar

    Published 2023-01-01
    “…Specifically, gene therapy has been shown to be effective in various clinical trials, and indeed, these trials have led to regulatory approvals, paving the way for gene therapies for other types of PGDs. …”
    Get full text
    Article
  9. 249

    “Lost in translation?” Animal research in the era of precision medicine by Hamideh Frühwein, Norbert W. Paul

    Published 2025-02-01
    “…Abstract Preclinical animal research has long been a cornerstone in evaluating the efficacy, toxicity, and safety of potential drug treatments before they proceed to human clinical trials. However, given the intricate nature of human physiology and the complexities of diseases such as cancer, this paper critically examines the role of animal experimentation in translational research, both from epistemological and ethical viewpoints. …”
    Get full text
    Article
  10. 250

    Erratum to ‘Efficacy and safety of local fibrinolytic therapy in intracranial hemorrhages: A systematic review and meta-analysis of randomised controlled trials’ [World Neurosurger... by Arun Babu Rajeswaran, Arshad Ali, Saleh Safi, Ahmed Eid Abdulghani Saleh

    Published 2025-01-01
    “…Methods: Medline, Embase, CINAHL Plus, Cochrane, Scopus, Web of science, clinical trials.gov, WHO and EU Clinical Trials Register were searched for RCTs only, on intra-clot fibrinolytics vs standard treatments for ICH and IVH. …”
    Get full text
    Article
  11. 251
  12. 252

    CAR T-cell detection scoping review: an essential biomarker in critical need of standardization by Naomi Taylor, Nirali N Shah, David P Turicek, Victoria M Giordani, Josquin Moraly

    Published 2023-05-01
    “…To evaluate whether subsequent manuscripts from a trial resolved these issues, we analyzed all subsequent manuscripts reporting on the 21 clinical trials, recording all expansion and persistence data. …”
    Get full text
    Article
  13. 253
  14. 254
  15. 255

    Intestinal microbiome as effective regulator of enteral and central nervous system activity by V. T. Ivashkin, K. V. Ivashkin

    Published 2018-08-01
    “…Accumulated data change the current concept on human microbiome and its potential, however further clinical trials required.…”
    Get full text
    Article
  16. 256

    Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis by D. V. Garbuzenko

    Published 2022-01-01
    “…Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. …”
    Get full text
    Article
  17. 257

    Understanding cancer predisposition in Singapore: what’s next by Jianbang Chiang, Tarryn Shaw, Joanne Ngeow

    Published 2023-01-01
    “…These include the potential for finding unexpected germline variants through somatic tumour testing, optimal risk management of patients with hereditary conditions involving moderate-penetrance genes, role of polygenic risk score in an under-represented Asian population, management of variants of uncertain significance, clinical trials in patients with germline pathogenic variants and technology in genetic counselling. …”
    Get full text
    Article
  18. 258

    Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases by A. A. Sheptulin, S. S. Kardasheva, A. A. Kurbatova

    Published 2021-04-01
    “…Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.…”
    Get full text
    Article
  19. 259

    A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment o... by Yan Gong, James Rogers, Christian Friedrich, Sanjay Patel, Alexander Staab, Jorge Luiz Gross, Daniel Polhamus, William Gillespie, Brigitta Ursula Monz, Silke Retlich

    Published 2013-03-01
    “…Comparison of two oral dipeptidyl peptidase (DPP)-4 inhibitors, sitagliptin and linagliptin, for type 2 diabetes mellitus (T2DM) treatment was used as an example.Design Systematic review with MBMA.Data sources MEDLINE, EMBASE, http://www.ClinicalTrials.gov, Cochrane review of DPP-4 inhibitors for T2DM, sitagliptin trials on Food and Drug Administration website to December 2011 and linagliptin data from the manufacturer.Eligibility criteria for selecting studies Double-blind, randomised controlled clinical trials, ≥12 weeks’ duration, that analysed sitagliptin or linagliptin efficacies as changes in glycated haemoglobin (HbA1c) levels, in adults with T2DM and HbA1c >7%, irrespective of background medication.Model development and application A Bayesian model was fitted (Markov Chain Monte Carlo method). …”
    Get full text
    Article
  20. 260

    Randomised controlled trial of topical kanuka honey for the treatment of rosacea by James Fingleton, Mark Weatherall, Richard Beasley, Irene Braithwaite, Janwillem Kocks, Mark Holliday, Andrew Corin, Colin Helm, Davitt Sheahan, Barney Montgomery, Judith Riley, Anna Hunt, Christopher Tofield

    Published 2015-06-01
    “…The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control.Conclusions Honevo is an effective treatment for rosacea.Trial registration number This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.…”
    Get full text
    Article